Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Alzheimer's Disease

Free Subscription Articles published in Ann Neurol Retrieve available abstracts of 65 articles: HTML format

Single Articles

September 2025
1. ABDELMOITY O, Wisch JK, Kennedy JT, Goyal M, et al
   Cross-Sectional FDG in Down Syndrome and Autosomal Dominant Alzheimer's Disease.
   Ann Neurol. 2025 Sep 22. doi: 10.1002/ana.78002.
   PubMed     Abstract available
   
   
   
2. BUCKLEY RF, Scott M, McGrath ER, Coughlan G, et al
   Midlife Steroid-Binding Globulin Levels and In Vivo Neuroimaging Measures of Tau in Older Men and Women.
   Ann Neurol. 2025;98:524-532.
   PubMed     Abstract available
   
   
   July 2025
3. GUNASEKARAN TI, Sanchez D, Reyes-Dumeyer D, Ventura R, et al
   Frequency of Microvascular Pathology and Hippocampal Atrophy on Magnetic Resonance Imaging in a Community Study of Alzheimer's Disease with Blood-Based Biomarkers.
   Ann Neurol. 2025 Jul 30. doi: 10.1002/ana.70006.
   PubMed     Abstract available
   
   
   
4. WOOD ALEXANDER M, Fischer DL, VandeVrede L, Nichols E, et al
   Sex Differences in Associations of Lewy Body Disease with Alzheimer's Disease and Cognitive Decline.
   Ann Neurol. 2025 Jul 11. doi: 10.1002/ana.27308.
   PubMed     Abstract available
   
   
   June 2025
5. MILA-ALOMA M, Tosun D, Schindler SE, Hausle I, et al
   Timing of Changes in Alzheimer's Disease Plasma Biomarkers as Assessed by Amyloid and Tau PET Clocks.
   Ann Neurol. 2025 Jun 20. doi: 10.1002/ana.27285.
   PubMed     Abstract available
   
   
   
6. REYES A, Zawar I, Punia V, Sarkis RA, et al
   Clinical and Cognitive Profiles of Individuals with Alzheimer's Disease and Comorbid Seizures.
   Ann Neurol. 2025 Jun 16. doi: 10.1002/ana.27284.
   PubMed     Abstract available
   
   
   April 2025
7. AFFANEH A, Linden AK, Tunc-Ozcan E, Tsai YH, et al
   Inhibition of Bone Morphogenetic Protein Signaling Prevents Tau Pathology in iPSC Derived Neurons and PS19 Mice.
   Ann Neurol. 2025;97:657-672.
   PubMed     Abstract available
   
   
   March 2025
8. LAGARDE J, Maiti P, Schonhaut DR, Blazhenets G, et al
   Amyloid PET in Sporadic Early- Versus Late-Onset Alzheimer's Disease: Comparison of the LEADS and ADNI Cohorts.
   Ann Neurol. 2025 Mar 17. doi: 10.1002/ana.27233.
   PubMed     Abstract available
   
   
   
9. ARRIOLA-INFANTE JE, Morcillo-Nieto AO, Zsadanyi SE, Franquesa-Mullerat M, et al
   Regional Brain Metabolism across the Alzheimer's Disease Continuum in Down Syndrome.
   Ann Neurol. 2025 Mar 14. doi: 10.1002/ana.27226.
   PubMed     Abstract available
   
   
   February 2025
10. KEUM M, Byun MS, Yi D, Ahn H, et al
    The Use of Antihypertensive Medication and In Vivo Alzheimer's Disease Pathology.
    Ann Neurol. 2025 Feb 17. doi: 10.1002/ana.27204.
    PubMed     Abstract available
    
    
    January 2025
11. WILLIAMS ME, Fennema-Notestine C, Bell TR, Lin SJ, et al
    Neuroimaging Predictors of Cognitive Resilience against Alzheimer's Disease Pathology.
    Ann Neurol. 2025 Jan 31. doi: 10.1002/ana.27186.
    PubMed     Abstract available
    
    
    
12. NOGUCHI-SHINOHARA M, Shuta K, Murakami H, Mori Y, et al
    Lecanemab-Associated Amyloid-beta Protofibril in Cerebrospinal Fluid Correlates with Biomarkers of Neurodegeneration in Alzheimer's Disease.
    Ann Neurol. 2025 Jan 6. doi: 10.1002/ana.27175.
    PubMed     Abstract available
    
    
    October 2024
13. YUAN J, Tao Q, Ang TFA, Liu C, et al
    The Relationship between Framingham Stroke Risk Profile on Incident Dementia and Alzheimer's Disease: A 40-Year Follow-Up Study Highlighting Female Vulnerability.
    Ann Neurol. 2024 Oct 15. doi: 10.1002/ana.27108.
    PubMed     Abstract available
    
    
    September 2024
14. ABDELNOUR C, Young CB, Shahid-Besanti M, Smith A, et al
    Plasma pTau181 Reveals a Pathological Signature that Predicts Cognitive Outcomes in Lewy Body Disease.
    Ann Neurol. 2024;96:526-538.
    PubMed     Abstract available
    
    
    
15. CHEN C, Lan Z, Tang X, Chen W, et al
    Human-Derived Induced GABAergic Progenitor Cells Improve Cognitive Function in Mice and Inhibit Astrocyte Activation with Anti-Inflammatory Exosomes.
    Ann Neurol. 2024;96:488-507.
    PubMed     Abstract available
    
    
    August 2024
16. MASURKAR AV, Marsh K, Morgan B, Leitner D, et al
    Factors Affecting Resilience and Prevention of Alzheimer's Disease and Related Dementias.
    Ann Neurol. 2024 Aug 17. doi: 10.1002/ana.27055.
    PubMed     Abstract available
    
    
    July 2024
17. BRIER MR, Schindler SE, Salter A, Perantie D, et al
    Unexpected Low Rate of Amyloid-beta Pathology in Multiple Sclerosis Patients.
    Ann Neurol. 2024 Jul 4. doi: 10.1002/ana.27027.
    PubMed     Abstract available
    
    
    June 2024
18. LAH JJ, Tian G, Risk BB, Hanfelt JJ, et al
    Lower Prevalence of Asymptomatic Alzheimer's Disease Among Healthy African Americans.
    Ann Neurol. 2024 Jun 25. doi: 10.1002/ana.26960.
    PubMed     Abstract available
    
    
    
19. SOLEIMANI-MEIGOONI DN, Smith R, Provost K, Lesman-Segev OH, et al
    Head-to-Head Comparison of Tau and Amyloid Positron Emission Tomography Visual Reads for Differential Diagnosis of Neurodegenerative Disorders: An International, Multicenter Study.
    Ann Neurol. 2024 Jun 18. doi: 10.1002/ana.27008.
    PubMed     Abstract available
    
    
    
20. KANAZAWA T, Sato W, Raveney BJE, Takewaki D, et al
    Pathogenic Potential of Eomesodermin-Expressing T-Helper Cells in Neurodegenerative Diseases.
    Ann Neurol. 2024;95:1093-1098.
    PubMed     Abstract available
    
    
    May 2024
21. DICARLO M, Pignataro P, Zecca C, Dell'Abate MT, et al
    Irisin Levels in Cerebrospinal Fluid Correlate with Biomarkers and Clinical Dementia Scores in Alzheimer Disease.
    Ann Neurol. 2024 May 23. doi: 10.1002/ana.26946.
    PubMed     Abstract available
    
    
    
22. CHEN XQ, Becker A, Albay R, Nguyen PD, et al
    gamma-Secretase Modulator BPN15606 Reduced Abeta42 and Abeta40 and Countered Alzheimer-Related Pathologies in a Mouse Model of Down Syndrome.
    Ann Neurol. 2024 May 15. doi: 10.1002/ana.26958.
    PubMed     Abstract available
    
    
    
23. HARRISON TM, Chadwick T, Pezzoli S, Lee J, et al
    Cognitive Trajectories and Alzheimer Disease Biomarkers: From Successful Cognitive Aging to Clinical Impairment.
    Ann Neurol. 2024 May 15. doi: 10.1002/ana.26964.
    PubMed     Abstract available
    
    
    
24. LAN G, Chen X, Yang J, Sun P, et al
    Microglial Reactivity Correlates with Presynaptic Loss Independent of beta-Amyloid and Tau.
    Ann Neurol. 2024;95:917-928.
    PubMed     Abstract available
    
    
    April 2024
25. GARCIA-CORDERO I, Anastassiadis C, Khoja A, Morales-Rivero A, et al
    Evaluating the Effect of Alzheimer's Disease-Related Biomarker Change in Corticobasal Syndrome and Progressive Supranuclear Palsy.
    Ann Neurol. 2024 Apr 5. doi: 10.1002/ana.26930.
    PubMed     Abstract available
    
    
    
26. SAKOWSKI SA, Koubek EJ, Chen KS, Goutman SA, et al
    Role of the Exposome in Neurodegenerative Disease: Recent Insights and Future Directions.
    Ann Neurol. 2024;95:635-652.
    PubMed     Abstract available
    
    
    
27. ARVANITAKIS Z, Capuano AW, Tong H, Mehta RI, et al
    Associations of Serum Insulin and Related Measures With Neuropathology and Cognition in Older Persons With and Without Diabetes.
    Ann Neurol. 2024;95:665-676.
    PubMed     Abstract available
    
    
    March 2024
28. 
    Retraction: 5-Lipoxygenase gene transfer worsens memory, amyloid, and tau brain pathologies in a mouse model of alzheimer disease.
    Ann Neurol. 2024 Mar 28. doi: 10.1002/ana.26938.
    PubMed     Abstract available
    
    
    
29. PALPATZIS E, Akinci M, Aguilar-Dominguez P, Garcia-Prat M, et al
    Lifetime Stressful Events Associated with Alzheimer's Pathologies, Neuroinflammation and Brain Structure in a Risk Enriched Cohort.
    Ann Neurol. 2024 Mar 11. doi: 10.1002/ana.26881.
    PubMed     Abstract available
    
    
    
30. LACHNER C, Craver EC, Babulal GM, Lucas JA, et al
    Disparate Dementia Risk Factors Are Associated with Cognitive Impairment and Rates of Decline in African Americans.
    Ann Neurol. 2024;95:518-529.
    PubMed     Abstract available
    
    
    
31. PAPP KV, Jutten RJ, Soberanes D, Weizenbaum E, et al
    Early Detection of Amyloid-Related Changes in Memory among Cognitively Unimpaired Older Adults with Daily Digital Testing.
    Ann Neurol. 2024;95:507-517.
    PubMed     Abstract available
    
    
    February 2024
32. VAN EGROO M, van Someren EJW, Grinberg LT, Bennett DA, et al
    Associations of 24-Hour Rest-Activity Rhythm Fragmentation, Cognitive Decline, and Postmortem Locus Coeruleus Hypopigmentation in Alzheimer's Disease.
    Ann Neurol. 2024 Feb 26. doi: 10.1002/ana.26880.
    PubMed     Abstract available
    
    
    
33. LI Y, Yen D, Hendrix RD, Gordon BA, et al
    Timing of Biomarker Changes in Sporadic Alzheimer's Disease in Estimated Years from Symptom Onset.
    Ann Neurol. 2024 Feb 24. doi: 10.1002/ana.26891.
    PubMed     Abstract available
    
    
    
34. PHAN TX, Baratono S, Drew W, Tetreault AM, et al
    Increased Cortical Thickness in Alzheimer's Disease.
    Ann Neurol. 2024 Feb 24. doi: 10.1002/ana.26894.
    PubMed     Abstract available
    
    
    
35. SALTIEL N, Tripodis Y, Menzin T, Olaniyan A, et al
    Relative Contributions of Mixed Pathologies to Cognitive and Functional Symptoms in Brain Donors Exposed to Repetitive Head Impacts.
    Ann Neurol. 2024;95:314-324.
    PubMed     Abstract available
    
    
    
36. KUCHENBECKER LA, Tipton PW, Martens Y, Brier MR, et al
    Diagnostic Utility of Cerebrospinal Fluid Biomarkers in Patients with Rapidly Progressive Dementia.
    Ann Neurol. 2024;95:299-313.
    PubMed     Abstract available
    
    
    
37. CHEN X, Toueg TN, Harrison TM, Baker SL, et al
    Regional Tau Deposition Reflects Different Pathways of Subsequent Neurodegeneration and Memory Decline in Cognitively Normal Older Adults.
    Ann Neurol. 2024;95:249-259.
    PubMed     Abstract available
    
    
    January 2024
38. VANCE JM, Farrer LA, Huang Y, Cruchaga C, et al
    Report of the APOE4 National Institute on Aging/Alzheimer Disease Sequencing Project Consortium Working Group: Reducing APOE4 in Carriers is a Therapeutic Goal for Alzheimer's Disease.
    Ann Neurol. 2024 Jan 5. doi: 10.1002/ana.26864.
    PubMed     Abstract available
    
    
    December 2023
39. BONOMI S, Lu R, Schindler SE, Bui Q, et al
    Relationships of Cognitive Measures with Cerebrospinal Fluid but not Imaging Biomarkers of Alzheimer Disease Vary between Black and White Individuals.
    Ann Neurol. 2023 Dec 1. doi: 10.1002/ana.26838.
    PubMed     Abstract available
    
    
    October 2023
40. ZHENG L, Rubinski A, Dennecke J, Luan Y, et al
    Combined Connectomics, MAPT Gene Expression, and Amyloid Deposition to Explain Regional Tau Deposition in Alzheimer's Disease.
    Ann Neurol. 2023 Oct 14. doi: 10.1002/ana.26818.
    PubMed     Abstract available
    
    
    
41. GRILL JD, Flournoy C, Dhadda S, Ernstrom K, et al
    Eligibility rates among racially and ethnically diverse US participants in Phase 2 and Phase 3 placebo-controlled, double-blind, randomized trials of lecanemab and elenbecestat in early Alzheimer's disease.
    Ann Neurol. 2023 Oct 13. doi: 10.1002/ana.26819.
    PubMed     Abstract available
    
    
    
42. DARK HE, Paterson C, Daya GN, Peng Z, et al
    Proteomic indicators of health predict Alzheimer's disease biomarker levels and dementia risk.
    Ann Neurol. 2023 Oct 6. doi: 10.1002/ana.26817.
    PubMed     Abstract available
    
    
    
43. SHAW LM, Galasko D
    Assessments of the Utilities of CSF NPTX2 for Disease Progression in Cognitively Normal Individuals Who Progress to Clinical MCI and AD.
    Ann Neurol. 2023;94:618-619.
    PubMed    
    
    
    
44. SOLDAN A, Oh S, Ryu T, Pettigrew C, et al
    NPTX2 in Cerebrospinal Fluid Predicts the Progression From Normal Cognition to Mild Cognitive Impairment.
    Ann Neurol. 2023;94:620-631.
    PubMed     Abstract available
    
    
    September 2023
45. HIRATA K, Matsuoka K, Tagai K, Endo H, et al
    Altered brain energy metabolism related to astrocytes in Alzheimer's disease.
    Ann Neurol. 2023 Sep 13. doi: 10.1002/ana.26797.
    PubMed     Abstract available
    
    
    August 2023
46. MINOGUE G, Kawles A, Zouridakis A, Keszycki R, et al
    Distinct Patterns of Hippocampal Pathology in Alzheimer's Disease with TDP-43.
    Ann Neurol. 2023 Aug 18. doi: 10.1002/ana.26762.
    PubMed     Abstract available
    
    
    
47. KOSIK KS
    Search Strategies for Alzheimer Protector Genes.
    Ann Neurol. 2023 Aug 13. doi: 10.1002/ana.26764.
    PubMed     Abstract available
    
    
    
48. YU L, Petyuk VA, Lopes KP, Tasaki S, et al
    Associations of VGF with Neuropathologies and Cognitive Health in Older Adults.
    Ann Neurol. 2023;94:232-244.
    PubMed     Abstract available
    
    
    
49. CHEN XQ, Sawa M, Becker A, Karachentsev D, et al
    Retromer Proteins Reduced in Down Syndrome and the Dp16 Model: Impact of APP Dose and Preclinical Studies of a gamma-Secretase Modulator.
    Ann Neurol. 2023;94:245-258.
    PubMed     Abstract available
    
    
    July 2023
50. KUHLENBAUMER G, Jensen-Kondering U, Margraf NG
    Decreased Cerebrospinal Fluid Amyloid Beta 38, 40, 42, and 43 Levels in Sporadic and Hereditary Cerebral Amyloid Angiopathy.
    Ann Neurol. 2023;94:205.
    PubMed    
    
    
    
51. LUCEY BP, Liu H, Toedebusch CD, Freund D, et al
    Suvorexant Acutely Decreases Tau Phosphorylation and Abeta in the Human CNS.
    Ann Neurol. 2023;94:27-40.
    PubMed     Abstract available
    
    
    June 2023
52. LUCEY BP, Bateman RJ
    Reply to Suvorexant for preventing Alzheimer's disease.
    Ann Neurol. 2023 Jun 28. doi: 10.1002/ana.26728.
    PubMed    
    
    
    
53. KAWADA T
    Suvorexant for preventing Alzheimer's disease.
    Ann Neurol. 2023 Jun 27. doi: 10.1002/ana.26733.
    PubMed    
    
    
    
54. DE KORT AM, Kuiperij HB, Marques TM, Jakel L, et al
    Decreased Cerebrospinal Fluid Amyloid beta 38, 40, 42, and 43 Levels in Sporadic and Hereditary Cerebral Amyloid Angiopathy.
    Ann Neurol. 2023;93:1173-1186.
    PubMed     Abstract available
    
    
    May 2023
55. NELSON PT, Schneider JA, Jicha GA, Duong MT, et al
    When Alzheimer's is LATE: Why does it matter?
    Ann Neurol. 2023 May 28. doi: 10.1002/ana.26711.
    PubMed     Abstract available
    
    
    
56. HOOSHMAND B, Appold F, Fissler P, Perneczky R, et al
    Markers of vitamin B12 status in relation to cerebrospinal fluid biomarkers of Alzheimer's disease and cognitive performance.
    Ann Neurol. 2023 May 12. doi: 10.1002/ana.26673.
    PubMed     Abstract available
    
    
    
57. ANDRE C, Champetier P, Rehel S, Kuhn E, et al
    Rapid Eye Movement Sleep, Neurodegeneration, and Amyloid Deposition in Aging.
    Ann Neurol. 2023;93:979-990.
    PubMed     Abstract available
    
    
    April 2023
58. NEDELEC T, Couvy-Duchesne B, Darves-Bornoz A, Couronne R, et al
    A comparison between early presentation of dementia with Lewy Bodies, Alzheimer's disease and Parkinson's disease: evidence from routine primary care and UK Biobank data.
    Ann Neurol. 2023 Apr 25. doi: 10.1002/ana.26670.
    PubMed     Abstract available
    
    
    
59. SHAHID M, Rawls A, Ramirez V, Ryman S, et al
    Illusory Responses across the Lewy Body Disease Spectrum.
    Ann Neurol. 2023;93:702-714.
    PubMed     Abstract available
    
    
    March 2023
60. MUSIEK ES, McDade E, Holtzman DM
    Lecanamab ushers in a new era of anti-amyloid therapy for Alzheimer's Disease.
    Ann Neurol. 2023 Mar 15. doi: 10.1002/ana.26643.
    PubMed    
    
    
    
61. PYUN JM, Park YH, Wang J, Bice PJ, et al
    Aberrant GAP43 gene expression is Alzheimer's disease pathology-specific.
    Ann Neurol. 2023 Mar 10. doi: 10.1002/ana.26637.
    PubMed    
    
    
    
62. LAN G, Guo T
    Reply to: "Aberrant GAP43 gene expression is Alzheimer's disease pathology-specific".
    Ann Neurol. 2023 Mar 10. doi: 10.1002/ana.26639.
    PubMed    
    
    
    
63. TROPEA TF, Albuja I, Cousins KAQ, Irwin DJ, et al
    Concomitant Alzheimer's Disease Pathology in Parkinson's Disease Dementia.
    Ann Neurol. 2023 Mar 9. doi: 10.1002/ana.26635.
    PubMed    
    
    
    
64. YOUNCE JR, Martin WRW, Perlmutter JS
    Reply to "Concomitant Alzheimer's Disease Pathology in Parkinson's Disease Dementia".
    Ann Neurol. 2023 Mar 9. doi: 10.1002/ana.26630.
    PubMed    
    
    
    February 2023
65. HORIE K, Li Y, Barthelemy NR, Gordon BA, et al
    Change in cerebrospinal fluid tau microtubule binding region detects symptom onset, cognitive decline, tangles, and atrophy in Dominantly Inherited Alzheimer's Disease.
    Ann Neurol. 2023 Feb 26. doi: 10.1002/ana.26620.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Alzheimer's Disease is free of charge.